Veru Inc (NASDAQ:VERU) Short Interest Down 36.6% in August
Veru Inc (NASDAQ:VERU) saw a significant decrease in short interest in August. As of August 31st, there was short interest totalling 16,300 shares, a decrease of 36.6% from the July 31st total of 25,700 shares. Based on an average daily volume of 230,700 shares, the short-interest ratio is currently 0.1 days. Approximately 0.0% of the shares of the stock are short sold.
A number of research analysts have commented on VERU shares. HC Wainwright reiterated a “buy” rating and issued a $4.50 price objective on shares of Veru in a research report on Friday, August 9th. Zacks Investment Research reissued a “hold” rating on shares of Veru in a research note on Saturday. Brookline Capital Management initiated coverage on Veru in a research report on Monday, July 29th. They set a “buy” rating and a $12.00 target price for the company. Finally, Cantor Fitzgerald initiated coverage on Veru in a research note on Monday, July 1st. They set an “overweight” rating and a $6.00 price target on the stock. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $5.71.
Shares of NASDAQ VERU remained flat at $$1.90 during mid-day trading on Wednesday. 92,993 shares of the stock traded hands, compared to its average volume of 104,181. Veru has a one year low of $1.18 and a one year high of $2.49. The company has a 50 day simple moving average of $2.03 and a two-hundred day simple moving average of $1.80. The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $124.87 million, a PE ratio of -4.87 and a beta of 0.43.
In related news, CEO Mitchell Shuster Steiner sold 30,000 shares of the business’s stock in a transaction that occurred on Friday, September 6th. The shares were sold at an average price of $1.93, for a total value of $57,900.00. Also, CFO Michele Greco acquired 20,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 20th. The stock was bought at an average price of $1.84 per share, with a total value of $36,800.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 47,000 shares of company stock worth $89,040 and have sold 80,000 shares worth $170,700. 29.50% of the stock is currently owned by corporate insiders.
Hedge funds have recently made changes to their positions in the business. Wedge Capital Management L L P NC acquired a new stake in Veru during the 2nd quarter worth $394,000. Renaissance Technologies LLC raised its position in shares of Veru by 183.1% during the 2nd quarter. Renaissance Technologies LLC now owns 262,160 shares of the company’s stock valued at $558,000 after acquiring an additional 169,550 shares during the last quarter. Geode Capital Management LLC raised its position in shares of Veru by 115.4% during the 4th quarter. Geode Capital Management LLC now owns 215,601 shares of the company’s stock valued at $301,000 after acquiring an additional 115,506 shares during the last quarter. BlackRock Inc. lifted its stake in shares of Veru by 65.4% in the 2nd quarter. BlackRock Inc. now owns 228,934 shares of the company’s stock valued at $487,000 after purchasing an additional 90,530 shares during the period. Finally, Perceptive Advisors LLC lifted its stake in shares of Veru by 1.4% in the 2nd quarter. Perceptive Advisors LLC now owns 1,445,000 shares of the company’s stock valued at $3,078,000 after purchasing an additional 20,000 shares during the period. 8.83% of the stock is currently owned by hedge funds and other institutional investors.
Veru Inc operates as an oncology and urology biopharmaceutical company. The company operates through two segments, Commercial, and Research and Development. It offers FC2 Female Condom for unintended pregnancy and sexually transmitted infections, including HIV/AIDS and the Zika virus; and PREBOOST benzocaine medicated individual wipes for the prevention of premature ejaculation.
Further Reading: Earnings Reports
Receive News & Ratings for Veru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Veru and related companies with MarketBeat.com's FREE daily email newsletter.